Lilly’s Zepbound tops Novo Nordisk’s Wegovy for weight loss in head-to-head trial
Companies competing for leadership in fast-growing market where supply continues to be an issue
Wegovy
Sharp increase in number of illegal weight loss drugs seized
HPRA warns of risks of illegal, counterfeit versions of drugs such as Ozempic and Wegovy, saying they pose ‘significant risk’
Obesity drugmaker Novo Nordisk misses profit forecast
Danish company employs about 450 people in Ireland
Novo Nordisk drops Dublin factory plan
Seen & Heard: Inheritance tax reduction, Press Up stake and Spar sale
Large increase in number of fake weight-loss drugs seized by watchdog in 2024
Officials warned consumers of risks from falsified versions of Ozempic and Wegovy
Ozempic and Wegovy maker Novo Nordisk set to build large manufacturing facility in Dublin
News of new factory comes after Danish group announced in December the purchase of drug manufacturing plant in Athlone in order to keep up with demand for weight-loss drugs
Ozempic maker Novo Nordisk buys Irish drug manufacturing plant in €85m deal
Danish weight loss and diabetes specialist is looking to develop a tablet form of its blockbuster obesity treatments
Weight-loss drugs hurt snack company shares
Concerns about weight-loss drugs hurting sales are ‘overblown’ say Citi analysts but investors are worried
The Truth About the ‘Skinny’ Jab: Are weight-loss injections a magic wand or potential health disaster?
Television: Presenter Anna Richardson explores how drugs like Ozempic and Wegovy work and the potential side effects
Obesity drugs make Novo Nordisk Europe’s biggest company
Company boosted by trial results showing weight loss drug also cuts risk of heart attack by 20%
Glanbia boss Siobhán Talbot leaves company in rude health
Food company boss has successfully steered group into high-margin nutritional space
Novo Nordisk says obesity pill leads to 15% weight loss
Danish drugmaker pushing for US and EU approval but has struggled to meet demand for its Ozempic and Wegovy drugs
Ireland on the cusp of obesity treatment revolution but high cost of drugs causing disquiet
Medications offer hope to patients with severe weight problems but will also be demanded by many for aesthetic reasons
Slimming drug Wegovy triggers significant forecast upgrade at Novo Nordisk
Demand for diabetes drug Ozempic, also used off label for weight loss, also fuels near doubling of sales and profit expectations
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices